Novavax (NVAX) Says Phase I Results in RSV Development Program Similar to Preclinical Data

Article Stock Quotes (1) Comments (0)

Novavax, Inc. (Nasdaq: NVAX) reported this week that Gregory Glenn, M.D., Senior Vice President and Chief Medical Officer of Novavax, reviewed recent preclinical and clinical findings from the company's respiratory syncytial virus (RSV) vaccine development program at the first Modern Vaccines Adjuvants and Delivery Systems conference in Copenhagen, Denmark. He reported that the findings from the recent Phase I trial were consistent with the preclinical results in relevant animal models, which indicated that the Novavax Fusion (F) protein nanoparticle RSV vaccine candidate was generally well-tolerated, highly immunogenic and produced functional antibodies that neutralized RSV.

There is currently no vaccine available to prevent RSV, which is the leading cause of bronchiolitis and pneumonia in infants under one year of age and a leading cause of pneumonia in older adults.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Pfizer (PFE) Discontinues Phase 3 Study of Inotuzumab Ozogamicin
• Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
• Regeneron (REGN) and Genentech Strike Deal on Worldwide EYLEA Sales

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?